Eton Pharmaceuticals announced on May 1 2026 the relaunch of HEMANGEOL®, the only FDA‑approved oral therapy for infantile hemangioma, a condition that affects 5,000–10,000 infants annually in the United States.
The relaunch includes the Eton Cares patient‑support program and an exclusive partnership with Anovo Specialty Pharmacy, ensuring rapid access and eliminating copays for eligible commercially insured patients. The program offers prescription fulfillment, insurance benefits investigation, and financial assistance.
The relaunch expands Eton’s rare‑disease portfolio to ten commercial products and aligns with the company’s strategy of acquiring and commercializing under‑commercialized assets. Management expects the launch to be accretive to 2026 earnings, with guidance for revenue exceeding $110 million and an adjusted EBITDA margin above 30 %.
CEO Sean Brynjelsen said, “We are excited to deliver another major product launch for the company. HEMANGEOL is a critical and time‑sensitive therapy where early treatment can meaningfully impact outcomes, and the only FDA‑approved treatment for infantile hemangiomas. With the integration of Eton Cares and a dedicated rare disease specialty pharmacy model, we are focused on helping patients start therapy quickly and ensuring families are supported from prescription through treatment.”
The announcement follows a strong Q4 2025 earnings report that saw revenue grow 83 % year‑over‑year, reinforcing investor confidence in Eton’s growth trajectory. The relaunch is expected to increase market penetration and generate additional revenue streams, further solidifying the company’s position in the rare‑disease market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.